3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
63
Lymphoma, Mantle-Cell
39
Waldenstrom Macroglobulinemia
18
Lymphoma, Large B-Cell, Diffuse
17
Lymphoma, Follicular
14
Recurrence
10
Lymphoma, B-Cell, Marginal Zone
10
Leukemia
9
Lymphoma, B-Cell
8
Lymphoma
8
Neoplasms
7
Lymphoma, Non-Hodgkin
5
Leukemia, Prolymphocytic
4
Hodgkin Disease
4
Multiple Myeloma
3
Leukemia, Myeloid, Acute
3
Leukemia, B-Cell
3
Hematologic Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms, Plasma Cell
2
Glioblastoma
2
Chromosome 17 deletion
2
Carcinoma, Non-Small-Cell Lung
2
Burkitt Lymphoma
2
Bronchiolitis Obliterans Syndrome
2
Brain Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Smoldering Multiple Myeloma
1
Prostatic Neoplasms
1
Primary Central Nervous System Lymphoma (PCNSL)
1
Interventions
Cyclophosphamide
21
Cytarabine
15
blinatumomab
13
fludarabine
12
Azacitidine
10
venetoclax
9
fludarabine phosphate
9
Blood Specimen Collection
8
Methotrexate
7
Lenalidomide
7
Dexamethasone
7
Rituximab
6
Mercaptopurine
6
Daunorubicin
6
Vincristine
5
daratumumab
4
Whole-Body Irradiation
4
Melphalan
4
Etoposide
4
Busulfan
4
obinutuzumab
3
Radiotherapy
3
Neoadjuvant Therapy
3
Maintenance
3
Liquid Biopsy
3
Immunotherapy, Adoptive
3
Idarubicin
3
Granulocyte Colony-Stimulating Factor
3
Drug Therapy
3
Doxorubicin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasm, Residual
×
ibrutinib
×
Clear all
NCT02666898
2025-11-26
ICLL07GAI
French Innovative Leukemia Organisation
Phase 2
Completed
135 enrolled